FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236086225> ?p ?o ?g. }

• W4236086225 endingPage "TPS8122" @default.
• W4236086225 startingPage "TPS8122" @default.
• W4236086225 abstract "TPS8122 Background: NSCLC is the leading cause of cancer death worldwide, exceeding breast, colon and prostate cancer combined. Most patients (pts) are diagnosed with advanced/recurrent disease. NSCLC therapies have incrementally improved overall survival (OS), but benefit has reached a plateau (median OS for late stage pts is just 1 yr). Squamous cell carcinoma (SCC) represents one quarter of NSCLC cases and has limited treatment options. Pemetrexed and bevacizumab are not approved in SCC, and molecularly targeted therapies have limited application. Single-agent chemotherapy is standard of care following progression with platinum-based doublet chemotherapy (Pt-doublet), resulting in median OS of approximately 7 months. Immune checkpoint blockade in NSCLC may promote tumor regression by reversing tumor-induced immunosuppression and restoring the antitumor immune response. Programmed death-1 (PD-1), an immune checkpoint receptor that negatively regulates T-cell activation, is upregulated in tumor infiltrating lymphocytes; expression of its ligand PD-L1 has been associated with poor prognosis in NSCLC. Nivolumab, a PD-1 receptor blocking antibody, showed encouraging antitumor activity in SCC pts in a phase 1 study, with objective responses (ORs) in 4 pts (27%) and stable disease ≥24 weeks in 1 pt (7%) (3 mg/kg; n=15) (Gettinger S et al; ESMO 2012 [Abstr 1237PD]). We describe an ongoing open-label phase 3 study to compare the clinical benefit of nivolumab vs docetaxel in advanced/metastatic SCC pts following failure of Pt-doublet. Methods: A total of 264 pts will be randomized 1:1 to nivolumab monotherapy 3 mg/kg IV every 2 weeks or docetaxel 75 mg/m 2 every 3 weeks until disease progression or unacceptable toxicity. Pts will be stratified by prior paclitaxel use and geographic region. Tumor response will be assessed using modified RECIST 1.1. The co-primary objectives are OR rate and OS. Secondary objectives include progression free survival, clinical benefit in PD ligand 1 (PD-L1+) and PD-L1– subgroups (archived tissue required for entry), durability of and time to OR, and pt proportion with symptom improvement. Clinical trial information: NCT01642004." @default.
• W4236086225 created "2022-05-12" @default.
• W4236086225 creator A5003212061 @default.
• W4236086225 creator A5003398407 @default.
• W4236086225 creator A5003723404 @default.
• W4236086225 creator A5012061864 @default.
• W4236086225 creator A5018401879 @default.
• W4236086225 creator A5053644519 @default.
• W4236086225 creator A5070256948 @default.
• W4236086225 creator A5075574557 @default.
• W4236086225 creator A5075877134 @default.
• W4236086225 creator A5085474533 @default.
• W4236086225 date "2013-05-20" @default.
• W4236086225 modified "2023-09-27" @default.
• W4236086225 title "A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC)." @default.
• W4236086225 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps8122" @default.
• W4236086225 hasPublicationYear "2013" @default.
• W4236086225 type Work @default.
• W4236086225 citedByCount "4" @default.
• W4236086225 countsByYear W42360862252014 @default.
• W4236086225 countsByYear W42360862252015 @default.
• W4236086225 countsByYear W42360862252022 @default.
• W4236086225 crossrefType "journal-article" @default.
• W4236086225 hasAuthorship W4236086225A5003212061 @default.
• W4236086225 hasAuthorship W4236086225A5003398407 @default.
• W4236086225 hasAuthorship W4236086225A5003723404 @default.
• W4236086225 hasAuthorship W4236086225A5012061864 @default.
• W4236086225 hasAuthorship W4236086225A5018401879 @default.
• W4236086225 hasAuthorship W4236086225A5053644519 @default.
• W4236086225 hasAuthorship W4236086225A5070256948 @default.
• W4236086225 hasAuthorship W4236086225A5075574557 @default.
• W4236086225 hasAuthorship W4236086225A5075877134 @default.
• W4236086225 hasAuthorship W4236086225A5085474533 @default.
• W4236086225 hasConcept C121608353 @default.
• W4236086225 hasConcept C126322002 @default.
• W4236086225 hasConcept C143998085 @default.
• W4236086225 hasConcept C2776256026 @default.
• W4236086225 hasConcept C2776694085 @default.
• W4236086225 hasConcept C2777240266 @default.
• W4236086225 hasConcept C2777701055 @default.
• W4236086225 hasConcept C2778239845 @default.
• W4236086225 hasConcept C2780030458 @default.
• W4236086225 hasConcept C2781190966 @default.
• W4236086225 hasConcept C71924100 @default.
• W4236086225 hasConceptScore W4236086225C121608353 @default.
• W4236086225 hasConceptScore W4236086225C126322002 @default.
• W4236086225 hasConceptScore W4236086225C143998085 @default.
• W4236086225 hasConceptScore W4236086225C2776256026 @default.
• W4236086225 hasConceptScore W4236086225C2776694085 @default.
• W4236086225 hasConceptScore W4236086225C2777240266 @default.
• W4236086225 hasConceptScore W4236086225C2777701055 @default.
• W4236086225 hasConceptScore W4236086225C2778239845 @default.
• W4236086225 hasConceptScore W4236086225C2780030458 @default.
• W4236086225 hasConceptScore W4236086225C2781190966 @default.
• W4236086225 hasConceptScore W4236086225C71924100 @default.
• W4236086225 hasIssue "15_suppl" @default.
• W4236086225 hasLocation W42360862251 @default.
• W4236086225 hasOpenAccess W4236086225 @default.
• W4236086225 hasPrimaryLocation W42360862251 @default.
• W4236086225 hasRelatedWork W138320 @default.
• W4236086225 hasRelatedWork W14327771 @default.
• W4236086225 hasRelatedWork W17235185 @default.
• W4236086225 hasRelatedWork W2073444 @default.
• W4236086225 hasRelatedWork W3819646 @default.
• W4236086225 hasRelatedWork W6095507 @default.
• W4236086225 hasRelatedWork W7348958 @default.
• W4236086225 hasRelatedWork W7623919 @default.
• W4236086225 hasRelatedWork W895291 @default.
• W4236086225 hasRelatedWork W17932051 @default.
• W4236086225 hasVolume "31" @default.
• W4236086225 isParatext "false" @default.
• W4236086225 isRetracted "false" @default.
• W4236086225 workType "article" @default.